Concerns have been raised over the availability of new psychoactive substances (NPSs) through online sales. While it may not be possible to reach agreement on an EU-wide approach to this issue, there is merit in gaining a wider understanding of the challenges presented by NPSs. Does the Commission have plans to conduct a study to determine the extent of this problem?
Many NPSs are made in China and are then imported into Europe and marketed, as recognised by the EU’s own drug monitoring agency. What representations has the Commission made to China to help address this serious public health issue?